Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group | Zendy

Andrew Bottomley | Zendy; Corneel Coens | Zendy; Stefan Suciu | Zendy; Mario Santinami | Zendy; W. Kruit | Zendy; Alessandro Testori | Zendy; Jeremy Marsden | Zendy; Cornelis J.A. Punt | Zendy; François Salès | Zendy; Martin Gore | Zendy; Rona M. MacKie | Zendy; Zvonko Kusić | Zendy; Reinhard Dummer | Zendy; Poulam Patel | Zendy; Dirk Schadendorf | Zendy; Alan Spatz | Zendy; Ulrich Keilholz | Zendy; Alexander M.M. Eggermont | Zendy

Open Access

Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group

Author(s) -

Andrew Bottomley,

Corneel Coens,

Stefan Suciu,

Mario Santinami,

W. Kruit,

Alessandro Testori,

Jeremy Marsden,

Cornelis J.A. Punt,

François Salès,

Martin Gore,

Rona M. MacKie,

Zvonko Kusić,

Reinhard Dummer,

Poulam Patel,

Dirk Schadendorf,

Alan Spatz,

Ulrich Keilholz,

Alexander M.M. Eggermont

Publication year - 2009

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2008.20.2069

Subject(s) - medicine , quality of life (healthcare) , pegylated interferon , melanoma , clinical endpoint , randomized controlled trial , cancer , adjuvant , adjuvant therapy , clinical trial , hazard ratio , surgery , oncology , immunology , confidence interval , hepatitis c virus , virus , nursing , cancer research , ribavirin

Interferon (IFN) -based adjuvant therapy in melanoma is associated with significant side effects, which necessitates evaluation of health-related quality of life (HRQOL). Our trial examined the HRQOL effects of adjuvant pegylated IFN-alpha-2b (PEG-IFN-alpha-2b) versus observation in patients with stage III melanoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research